MacroGenics | MGNX - Sales Revenues


MacroGenics reported $72.84M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Genmab DKK 5.86B 580M Jun/2025
Geron USD 48.02M 820K Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
J&J USD 24.6B 610M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
MacroGenics USD 72.84M 50.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025